A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Cancer

In brief

The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.

Key facts

Study ID

NCT01204996

Run by

Centocor, Inc.

People needed

53

Starts

2010-05-01

Expected to finish

2011-11-01

Last updated by the study team

2012-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documentation of an advanced solid tumor
• No more than 2 previous anticancer therapies
• good performance status
• adequate bone marrow, liver, and renal function / adequate blood test values
• willing to use birth control measures

You may not qualify if…

• No residual toxicities resulting from previous therapy
• no known allergies, hypersensitivity, or intolerance to antibodies or chemotherapies
• clinically significant bleeding or requiring concurrent therapeutic dose of anticoagulation

Where it is running

• Study site — Detroit, Michigan, United States
• Study site — Tacoma, Washington, United States
• Study site — Barcelona, Spain
• Study site — Madrid, Spain
• Study site — PAU de Sanchinarro, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.